Logo

C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson's Disease

Share this

C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost for Parkinson's Disease

Shots:

  • The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the companies on validated targets
  • The focus of the agreement is to advance C4XD drug discovery pipeline by validating targets identified by C4XD’s Taxonomy3 with the addition of PhoreMost’s SITESEEKER and provides chemical starting points to launch drug discovery programmes
  • Taxonomy3 is a novel in silico platform technology utilizing mathematical algorithms to identify drug targets.  SITESEEKER is based on PROTEINi’ technology providing 3D biological shape of natural protein fragment libraries

Click here to read full press release/ article | Ref: C4XD | Image: Pinterest


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions